An Integrated Microarray Analysis Reveals Significant Diagnostic and Prognostic Biomarkers in Pancreatic Cancer

Abstract

Departmental sources Background:Pancreatic cancer (PAC) is a lethal cancer and it is essential to develop accurate diagnostic and prognostic biomarkers for PAC. Material/Methods:An integrated microarray analysis of PAC was conducted to identify differentially expressed genes (DEGs) between PAC and non-tumor controls. Expression of DEGs were further confirmed by The Cancer Genome Atlas and the Genotype-Tissue Expression. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis, and protein-protein integration network construction were performed to further research the biological functions of DEGs. Receiver-operating characteristic analysis and survival analysis were used to evaluate the diagnostic and prognostic value of DEGs for PAC. Results:Seventeen microarray datasets were downloaded from Gene Expression Omnibus to conduct the integrated microarray analysis. A total of 1136 DEGs (596 upregulated and 540 downregulated DEGs) in PAC tissues compared with non-tumor controls were identified. Pancreatic secretion (Kegg: 04972), insulin signaling pathway (Kegg: 04910), and several cancer-related pathways including pathways in cancer (Kegg: 05200), MAPK signaling pathway (Kegg: 04010), and pancreatic cancer (Kegg: 05212) were enriched for DEGs in PAC. Seven DEGs (AHNAK2, CDH3, IFI27, ITGA2, LAMB3, SLC6A14, and TMPRSS4) were found to have both great diagnostic and prognostic value for PAC. High expression of these 7 DEGs were significantly associated with poor prognosis of patients with PAC. Conclusions:These 7 DEGs might be potential diagnostic and prognostic biomarkers for PAC and help uncovering the mechanism of PAC.

ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: an integrated bioinformatics analysis

“…It is worth noting that DEGs in PDAC have already been demonstrated in several studies 6 – 8 , 26 – 31 . However, the results were not consistent, which could be due to the differences in the selection of datasets and statistical procedures.…”

“…For Scopus the following criteria were used: TITLE-ABS-KEY (pancreatic AND ductal AND adenocarcinoma OR pancreatic AND cancer OR pancreatic AND neoplasm AND bioinformatics AND microarray AND analysis). Peer-reviewed studies were considered for the last 10-years, and after a comprehensive analysis, nine studies were selected 6 – 8 , 26 – 31 .…”

“…The gene expression profiles from diverse microarray platforms are submitted to several public databases, including Gene Expression Omnibus (GEO: https://www.ncbi.nlm.nih.gov/gds/ ). Several previous studies used gene expression microarray technology to underpinning the DEGs of PDAC in recent years 6 – 8 . However, the results were inconsistent, and various aspects remain unclear due to sample heterogeneity.…”

Amino Acid Transporter SLC6A14 (ATB0,+) – A Target in Combined Anti-cancer Therapy

“…Based on the data from Protein Atlas 2 survival prognosis at either low or high SLC6A14 expression level was found prognostic for pancreatic cancer, being unfavorable at high SLC6A14 expression ( Table 2), although the cohorts were relatively small. Another study using an integrated microarray analysis of differentially expressed genes detected 596 upregulated and 540 downregulated genes in pancreatic cancer, when compared with non-tumor control (Yang et al, 2020). SLC6A14 was found among possible diagnostic and prognostic genes, together with AHNAK2, CDH3, IFI27, ITGA2, LAMB3, and TMPRSS4.…”

“…SLC6A14 was found among possible diagnostic and prognostic genes, together with AHNAK2, CDH3, IFI27, ITGA2, LAMB3, and TMPRSS4. The upregulated genes were annotated to such processes as cell proliferation, apotosis, protein binding and the analysis of enriched genes showed involvement in pancreatic secretion and p53 signaling, MAPK signaling and insulin signaling pathways (Yang et al, 2020).…”